Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Non-Current Deffered Revenue (2020 - 2022)

Historic Non-Current Deffered Revenue for Therapeutics (RAPT) over the last 3 years, with Q1 2022 value amounting to $241000.0.

  • Therapeutics' Non-Current Deffered Revenue fell 8882.71% to $241000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $241000.0, marking a year-over-year decrease of 8882.71%. This contributed to the annual value of $2.2 million for FY2021, which is 160.18% down from last year.
  • According to the latest figures from Q1 2022, Therapeutics' Non-Current Deffered Revenue is $241000.0, which was down 8882.71% from $2.2 million recorded in Q4 2021.
  • In the past 5 years, Therapeutics' Non-Current Deffered Revenue ranged from a high of $3.3 million in Q1 2020 and a low of $241000.0 during Q1 2022
  • Over the past 3 years, Therapeutics' median Non-Current Deffered Revenue value was $2.2 million (recorded in 2021), while the average stood at $2.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first crashed by 160.18% in 2021, then plummeted by 8882.71% in 2022.
  • Quarter analysis of 3 years shows Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2020, then dropped by 1.6% to $2.2 million in 2021, then tumbled by 88.79% to $241000.0 in 2022.
  • Its last three reported values are $241000.0 in Q1 2022, $2.2 million for Q4 2021, and $2.1 million during Q3 2021.